CytomX Therapeutics Inc


Prices are adjusted according to historical splits.

CytomX Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$112.34 million
Book Value:
Revenue TTM:
$71.94 million
Operating Margin TTM:
Gross Profit TTM:
$69.57 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

CytomX Therapeutics Inc had its IPO on 2015-10-08 under the ticker symbol CTMX.

The company operates in the Healthcare sector and Biotechnology industry. CytomX Therapeutics Inc has a staff strength of 174 employees.

Stock update

Shares of CytomX Therapeutics Inc opened at $1.7 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $1.65 - $1.73, and closed at $1.7.

This is a +0.59% increase from the previous day's closing price.

A total volume of 896,082 shares were traded at the close of the day’s session.

In the last one week, shares of CytomX Therapeutics Inc have slipped by -12.37%.

CytomX Therapeutics Inc's Key Ratios

CytomX Therapeutics Inc has a market cap of $112.34 million, indicating a price to book ratio of 3.8062 and a price to sales ratio of 1.4467.

In the last 12-months CytomX Therapeutics Inc’s revenue was $71.94 million with a gross profit of $69.57 million and an EBITDA of $-89148000. The EBITDA ratio measures CytomX Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, CytomX Therapeutics Inc’s operating margin was -127.4% while its return on assets stood at -19.17% with a return of equity of -139.27%.

In Q3, CytomX Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.8%.

CytomX Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -1.8. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CytomX Therapeutics Inc’s profitability.

CytomX Therapeutics Inc stock is trading at a EV to sales ratio of 0.7429 and a EV to EBITDA ratio of 0.6936. Its price to sales ratio in the trailing 12-months stood at 1.4467.

CytomX Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$226.49 million
Total Liabilities
$97.84 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

CytomX Therapeutics Inc ended 2023 with $226.49 million in total assets and $0 in total liabilities. Its intangible assets were valued at $226.49 million while shareholder equity stood at $28.47 million.

CytomX Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $97.84 million in other current liabilities, 1000.00 in common stock, $-605089000.00 in retained earnings and $949000.00 in goodwill. Its cash balance stood at $95.04 million and cash and short-term investments were $194.29 million. The company’s total short-term debt was $3,961,000 while long-term debt stood at $0.

CytomX Therapeutics Inc’s total current assets stands at $200.28 million while long-term investments were $0 and short-term investments were $99.25 million. Its net receivables were $1.71 million compared to accounts payable of $5.18 million and inventory worth $0.

In 2023, CytomX Therapeutics Inc's operating cash flow was $-410000.00 while its capital expenditure stood at $410000.

Comparatively, CytomX Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

CytomX Therapeutics Inc stock is currently trading at $1.7 per share. It touched a 52-week high of $3.02 and a 52-week low of $3.02. Analysts tracking the stock have a 12-month average target price of $2.82.

Its 50-day moving average was $2.33 and 200-day moving average was $1.76 The short ratio stood at 1.12 indicating a short percent outstanding of 0%.

Around 134.1% of the company’s stock are held by insiders while 5789.3% are held by institutions.

Frequently Asked Questions About CytomX Therapeutics Inc

The stock symbol (also called stock or share ticker) of CytomX Therapeutics Inc is CTMX

The IPO of CytomX Therapeutics Inc took place on 2015-10-08

Similar Industry Stocks (Biotechnology)

Last Price
Agios Pharm (AGIO)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company’s product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.


151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080